News Sentiment

ALMS sentiment intelligence

Alumis Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 23.41 Week of 19 Jun 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

74/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-3.1% over one week, +6.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Alumis | 4: Statement of changes in beneficial ownership of securities-10% Owner Foresite Capital Management VI LLC

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 74/100 classification
One-week reaction -3.1% Price reacting lower
Trend fit Trend active 6.3% over four weeks
Fair value 107.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 29
Neutral 30
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 9
simplywall.st 6
Moomoo 4
GuruFocus 3
TradingKey 2
Simply Wall Street 2
Benzinga 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 23
Analyst action 10
Regulatory and legal 3
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
Moomoo Direct company coverage

Alumis | 4: Statement of changes in beneficial ownership of securities-10% Owner Foresite Capital Management VI LLC

This document is a statement of changes in beneficial ownership of securities for Alumis, specifically involving a 10% owner, Foresite Capital Management VI LLC. Such statements are routinely filed with regulatory bodies to disclose significant changes in ownership by major share

Tone
Neutral 50/100
Event
Regulatory and legal
Published
21 Jun 2026 16:12
Source
Moomoo
TradingKey Direct company coverage

Alumis Inc (ALMS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Alumis Inc (ALMS) currently has an earnings forecast score of 9.09, placing it favorably within the Biotechnology & Medical Research industry. Analysts have assigned an average price target of $18.00 for ALMS, with a majority recommending a "Buy" rating. The company's expected re

Tone
Positive 71/100
Event
Earnings
Published
17 Jun 2026 19:38
Source
TradingKey
TradingKey Direct company coverage

Alumis Inc (ALMS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Alumis Inc (ALMS), detailing its business segments, regional revenue, and profit contribution. It notes that significant financial data for FY2025, including quarterly breakdowns, has not yet been disclosed by the company. The current

Tone
Neutral 50/100
Event
Earnings
Published
16 Jun 2026 14:11
Source
TradingKey
GuruFocus Direct company coverage

Alumis (ALMS) Sees 10.3% Surge, Reaching $23.06

Alumis Inc (ALMS) experienced a 10.3% stock surge, closing at $23.06, driven by positive market sentiment and investor interest in its biotechnology therapies. Despite a low GF Score™ of 14/100 due to profitability concerns, the company exhibits strong financial stability with an

Tone
Positive 73/100
Event
Market update
Published
14 Jun 2026 02:09
Source
GuruFocus
TechStock² Direct company coverage

Alumis Shares Surge 16% as Traders Eye New Drug Move

Alumis Inc. (ALMS) shares jumped 15.55% to $24.15 on high volume as traders anticipate key clinical and regulatory milestones for its main drug, envudeucitinib. The late-stage biopharma company, which currently operates at a loss, is expecting Phase 2b LUMUS lupus data in Q3 2026

Tone
Positive 71/100
Event
Regulatory and legal
Published
13 Jun 2026 00:39
Source
TechStock²
Moomoo Direct company coverage

Alumis | SCHEDULE 13D/A: Others

This article consists solely of the word "Document," indicating it is likely a placeholder or a very brief record of a filing or piece of content. Without additional information, it's impossible to provide further context or detail.

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 23:39
Source
Moomoo
Kavout Direct company coverage

Has Alumis's Envudeucitinib Redefined Psoriasis Treatment

Alumis's envudeucitinib, an oral TYK2 inhibitor, has shown strong Phase 3 results for plaque psoriasis, demonstrating high skin clearance rates and quality of life improvements. Its differentiated profile, including superior efficacy to apremilast and maximal 24-hour TYK2 inhibit

Tone
Positive 82/100
Event
Regulatory and legal
Published
30 May 2026 02:09
Source
Kavout
ChartMill Direct company coverage

ALMS Stock Chart | ALUMIS INC (NASDAQ:ALMS)

This article provides a stock chart for ALUMIS INC (NASDAQ: ALMS) from ChartMill.com. It shows the current stock price as 21.6 USD, indicating a 0.93% increase at market close on May 29, 2026. The article highlights various financial analysis tools available on the ChartMill plat

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 07:09
Source
ChartMill
Stock Titan Direct company coverage

Alumis (ALMS) Chief Medical Officer exercises stock options for 26,852 shares

Alumis Inc.'s Chief Medical Officer, Jorn Drappa, exercised stock options to acquire a total of 26,852 shares of common stock. These exercises, reported on May 22, 2026, involved two blocks of shares at strike prices of $5.06 and $8.84 per share. No open-market purchases or sales

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 23:10
Source
Stock Titan
Insider Monkey Direct company coverage

10 Under-the-Radar Stocks with Massive Upside for 2026

This article highlights several under-the-radar stocks with massive upside potential for 2026, focusing on Alumis Inc. (NASDAQ:ALMS) as an example. Alumis Inc. has a 79.4% analyst consensus upside and has received multiple price target increases following positive Q1 results and

Tone
Positive 72/100
Event
Analyst action
Published
27 May 2026 20:10
Source
Insider Monkey
GuruFocus Direct company coverage

TOWERVIEW LLC's Alumis Inc(ALMS) Holding History

This article details TOWERVIEW LLC's holding history in Alumis Inc (ALMS). As of March 31, 2026, TOWERVIEW LLC holds 222,294 shares valued at $4.90 million, representing 3.16% of their portfolio. The firm has made 5 purchases and 1 sale of ALMS shares since Q2 2024, resulting in

Tone
Positive 74/100
Event
Market update
Published
27 May 2026 19:39
Source
GuruFocus
Simply Wall Street Direct company coverage

How Alumis’ Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) Investors

Alumis Inc. recently reported Q1 2026 results with a significant revenue drop from US$17.39 million to US$1.74 million but a narrowed net loss of US$93.05 million, down from US$98.96 million. Despite the revenue slide, the company reduced its basic loss per share to US$0.74 from

Tone
Neutral 50/100
Event
Earnings
Published
25 May 2026 00:09
Source
Simply Wall Street
Benzinga Direct company coverage

Alumis Analyst Ratings and Price Targets | NASDAQ:ALMS

This article provides an overview of analyst ratings and price targets for Alumis Inc. (NASDAQ:ALMS). Based on 12 analysts, Alumis has a consensus price target of $36.73, with a high of $55 and a low of $14. The most recent analyst ratings suggest an implied 89.22% upside for the

Tone
Positive 65/100
Event
Analyst action
Published
23 May 2026 04:09
Source
Benzinga
GuruFocus Direct company coverage

ALMS Maintained by Chardan Capital -- Price Target Raised to $40

Chardan Capital analyst Janani Sundararajan has reaffirmed a 'Buy' rating for Alumis (ALMS) and increased the price target to $40.00 from $38.00, reflecting confidence in the company's growth potential despite its low GF Score™ of 14/100. Alumis, a clinical-stage biopharmaceutica

Tone
Positive 71/100
Event
Analyst action
Published
19 May 2026 14:08
Source
GuruFocus
TipRanks Direct company coverage

Alumis price target raised to $40 from $38 at Chardan

Chardan has increased its price target for Alumis (ALMS) to $40 from $38, maintaining a Buy rating on the shares. This adjustment reflects updated pricing assumptions for envudeucitinib, minor changes in psoriasis penetration, and revised financial data following the company's fi

Tone
Positive 74/100
Event
Analyst action
Published
19 May 2026 13:08
Source
TipRanks
Stock Titan Direct company coverage

[ARS] ALUMIS INC. SEC Filing

This article reports on an ARS SEC filing by Alumis Inc. (ALMS) on May 18, 2026, at 04:29 PM. The filing is categorized with low impact and neutral sentiment. The article also provides recent news and SEC filings related to Alumis Inc., along with key stock data.

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 02:39
Source
Stock Titan
Stock Titan Direct company coverage

[DEF 14A] ALUMIS INC. Definitive Proxy Statement

Alumis Inc. has filed a Definitive Proxy Statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held virtually on June 30, 2026. Stockholders are asked to elect three Class II directors and ratify the appointment of PricewaterhouseCoopers LLP as the independent aud

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 01:38
Source
Stock Titan
IndexBox Direct company coverage

Cormorant Asset Management Acquires 313,645 Shares of Alumis in Q1 2026

Cormorant Asset Management has acquired 313,645 shares of Alumis during Q1 2026, investing $7.84 million in the biotechnology company. This investment increased Cormorant's stake value in Alumis by $51.52 million and represents 4.37% of its 13F assets. Alumis shares have surged 4

Tone
Positive 70/100
Event
Deals and strategy
Published
17 May 2026 19:09
Source
IndexBox
Simply Wall Street Direct company coverage

Alumis (Nasdaq:ALMS) - Aktienanalyse

Alumis Inc. (Nasdaq:ALMS) is a clinical-stage biopharmaceutical company focused on developing and commercializing drugs for autoimmune diseases. The company's stock is currently trading at US$22.04, with analysts estimating a fair value of US$40.1, indicating it is undervalued. R

Tone
Positive 72/100
Event
Market update
Published
16 May 2026 14:39
Source
Simply Wall Street
MSN Direct company coverage

HC Wainwright & Co. downgrades Alumis (ALMS)

This article reports that HC Wainwright & Co. has downgraded its rating for Alumis (ALMS). The specific details or reasons for the downgrade are not provided within the given content.

Tone
Negative 30/100
Event
Analyst action
Published
15 May 2026 23:38
Source
MSN